For the year ending 2025-12-31, CLNN had -$6,966K decrease in cash & cash equivalents over the period. -$18,585K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -26,173 |
| Depreciation | 1,495 |
| Non-cash lease expense | 571 |
| Issuance costs for common stock warrant liabilities | 0 |
| Loss on initial issuance of equity | 0 |
| Issuance of common stock as payment of outstanding indebtedness | -8 |
| Change in fair value of common stock warrant liabilities | 522 |
| Change in fair value of derivative liabilities | -363 |
| Change in fair value of clene nanomedicine contingent earn-out liability | 0 |
| Change in fair value of initial stockholders contingent earn-out liability | 0 |
| Stock-based compensation expense | 6,382 |
| Loss on extinguishment of notes payable | 0 |
| Loss on disposal of property and equipment | 0 |
| Accretion of debt discount | 1,027 |
| Non-cash interest income on marketable securities | 0 |
| Non-cash interest expense on notes payable | -612 |
| Accounts receivable | -64 |
| Inventory | -31 |
| Prepaid expenses and other current assets | -119 |
| Accounts payable | -348 |
| Accrued liabilities | -2,219 |
| Operating lease obligations | -1,000 |
| Net cash used in operating activities | -18,546 |
| Purchases of marketable securities | 0 |
| Proceeds from maturities of marketable securities | 0 |
| Purchases of property and equipment | 39 |
| Net cash provided by (used in) investing activities | -39 |
| Proceeds from exercise of stock options | 0 |
| Proceeds from issuance of common stock, warrants, and pre-funded warrants, net of offering costs | 10,402 |
| Proceeds from the issuance of debt and derivative liabilities | 1,500 |
| Payments of notes payable | 384 |
| Payments of finance lease obligations | 0 |
| Net cash provided by (used in) financing activities | 11,518 |
| Effect of foreign exchange rate changes on cash and restricted cash | 101 |
| Net decrease in cash, cash equivalents and restricted cash | -6,966 |
| Cash, cash equivalents and restricted cash beginning of period | 12,213 |
| Cash, cash equivalents and restricted cash end of period | 5,247 |
Clene Inc. (CLNN)
Clene Inc. (CLNN)